Effects of Navelbine and Docetaxel on Gene Expression in Human Lung Cancer Cell Lines

Cell Biochemistry and Biophysics

Volumn 61, Issue 3, 2011, Pages 665-671

  Shi, Guangyue ^a   Cai, Li ^a   Jiang, Wei ^a   Sui, Guangjie ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor drugs; cDNA Macroarray; Docetaxel; Gene expression; Lung cancer; MTT; Navelbine

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; NAVELBINE; TAXOID; TRANSCRIPTOME; VINBLASTINE;

ARTICLE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; TAXOIDS; TRANSCRIPTOME; VINBLASTINE;

EID: 81155161847     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9252-y     Document Type: Article

References (18)

1. Lourda, M., Trougakos, I. P., & Gonos, E. S. (2007). Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein. International Journal of Cancer, 120, 611-622.
2. Ohira, T., Akutagawa, S., Usuda, J., et al. (2002). Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. Oncological Report, 9, 723-728.
3. Califano, A., Stolovitzky, G., & Tu, Y. (2000). Analysis of gene expression microarrays for phenotype classification. Proceedings of the International Conference on Intelligent Systems for Molecular Biology, 8, 75-85.
4. Shimoyama, Y., Kubota, T., Watanabe, M., Ishibiki, K., & Abe, O. (1989). Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. Journal of Surgical Oncology, 41, 12-18.
5. Reed, L. J., & Muench, H. A. (1938). Simple method of estimating fifty percent end points. The American Journal of Epidemiology, 27, 493.
6. Gemma, K., Takenaka, Y., Hosoya, Y., et al. (2001). Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. European Journal of Cancer, 37, 1554-1561.
7. Le Chevalier, T., Brisgand, D., Douillard, J. Y., et al. (1994). Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. Journal of Clinical Oncology, 12, 360-367.
8. Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., et al. (1998). Randomized trial comparing cisplatin with navelbine in the treatment of advanced non-small cell lung cancer: A southwest oncology group study. Journal of Clinical Oncology, 16, 2459-2465.
9. Adjei, A. A., Argiris, A., & Murren, J. R. (1999). Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Seminars in Oncology, 26, 32-40.
10. Robinet, G., Thomas, P., Perol, M., et al. (2000). Phase II study of docetaxel in inoperable advanced non small cell lung cancer. Bulletin du Cancer, 87, 253-258.
11. Provencio, M., de las Penas, R., Cobo, M., et al. (2008). Cisplatin (CDDP) plus vinorelbine (NVB) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Retrospective analysis to improve the patient's convenience on day 8 NVB administration. Journal of Clinical Oncology, 26, 19049.
12. Yan, S., Weilian, L., Zhongzhen, G., et al. (1998). Docetaxel treat breast cancer and lung cancer in late period. The Chinese New Medicine Magazine, 7, 165-167.
13. Khan, J., Bitter, M. L., Chen, Y., et al. (1999). DNA microarray technology: The antiipafeo impact on the study of human disease. Biochemica et Biophysica Acta, 1423, M17-M28.
14. Ildsmith, S. E., & Elcock, F. J. (2001). Microarrays and the microscope. Molecular Pathology, 54, 8-16.
15. Scherf, U., Ross, D. T., Waltham, M., et al. (2000). A gene expression database for the molecular pharmacology of cancer. Nature Genetics, 24, 236-244.
16. Dan, S., Tsunoda, T., Kitahara, O., et al. (2002). An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell stains. Cancer Research, 62, 1139-1147.
17. Bissery, M. C., Nohynek, G., Sanderink, G. J., & Lavelle, F. (1995). Docetaxel (Taxotere). A review of preclinical and clinical experience. Part 1: Preclinical experience. Anticancer Drugs, 6, 339-368.
18. van Ark-Otte, J., Samelis, G., Rubio, G., Lopez, S. J. B., Pinedo, H. M., & Giaccone, G. (1998). Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncology Reports, 5, 249-255.